Akums Drugs & Pharmaceuticals Ltd Walk-in interview 2021.B.Sc/B.Sc(Hons) in Chemistry PG :M.Sc/MS in Chemistry for Executive/ Sr. Executive/ Patent Analyst/ API & Formulation At India- Mumbai.Akums Drugs & Pharmaceuticals Ltd Notification full detailes below.Interested Candidates Apply Now.
- Important Vacancy details:
- Company Name:Akums Drugs & Pharmaceuticals Ltd
- Post Name: Executive/ Sr. Executive/ Patent Analyst/ API & Formulation
- Qualification: B.Sc/B.Sc(Hons) in Chemistry PG :M.Sc/MS in Chemistry
- Minimum Experience:02-3 years experience
- Location: India- Mumbai
- Salary:NA
- Openings:NA
- Contact Number:Ms. Nikita Sehgal @ 8800461116
- Selection Process: The selection will be on the basis of Interview.
Job Description: We have Hiring For Executive/ Sr. Executive/ Patent Analyst/ API & Formulation in Akums Drugs & Pharmaceuticals Ltd !
- Candidate must be registered Patent agent.
- Should have through Knowledge of Patent searches and analytics.
- Should have knowledge about Indian, European and USA patent laws.
- Conduct Prior art/FTO/Patentability/Invalidity/Sequence/Structure search.
- Conduct FTO/Clearance searches for both API and formulation for both Indian & ROW markets.
- Drafting & Filling of Patent application, Reply to Examination reports, Attend Oral Hearing.
About Company:
ClinSync is a consolidated dream that has come true of a like minded medical doctors focused on research. Our vision is to be a preferred and globally respected research partner for Pharmaceutical, Biotech, Medical Devices and Healthcare IT companies. Our mission is to achieve our vision by conducting the duties in highly ethical environment and providing ClinSync services with honesty, quality and compliance to our clients, stake holders and employees; We also advocate the clinicians, researchers and patients in best possible ethical ways to expedite the development of new medicines and/or technologies that alleviate suffering of the patients. This is based on certain values of Honesty, Ethics, LeaAdership and excelLence (HEAL) and also through a novel Investigator Delivery Model (IDM)